ArticleArchives of osteoporosis2025
Community-based evaluation of Saudi FRAX with and without BMD in Riyadh, Saudi Arabia.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is a growing health burden requiring early risk assessment. In Saudi adults ≥ 60 years, FRAX scores with and without BMD showed minimal reclassification, with most shifts toward higher risk in younger groups. FRAX without BMD offers reliable stratification, supporting its use as a first-line screening tool.
methodsA retrospective cross-sectional study included patients aged ≥ 60 years attending family medicine clinics at King Faisal Specialist Hospital & Research Centre, Riyadh, undergoing DXA screening between January 1, 2016, and December 31, 2022. Baseline variables were age, sex, and BMI. FRAX variables assessed were family history of hip fracture (HF), prior fracture, smoking, glucocorticoid use, rheumatoid arthritis, and alcohol intake. Fracture risk was categorized using fixed and age-specific thresholds; differences in FRAX scores and reclassification patterns were evaluated.
resultsAmong 1,429 patients (mean age 68.07 ± 6.62 years), FRAX scores for major osteoporotic fracture (MOF) and HF) differed significantly with and without BMD. Subgroup analysis revealed no significant differences within specific age ranges (70-75 years for MOF and 60-75 years for HF) or among men across all age groups. Reclassification occurred in a small subset of patients, predominantly shifting toward higher-risk categories, particularly in younger age groups.
conclusionFRAX without BMD provides robust risk stratification, with minimal impact on reclassification across age categories. These results highlight its utility as a primary screening strategy, whereas BMD assessment may be reserved for cases requiring further refinement. PURPOSE: Osteoporosis is a skeletal disorder defined by reduced bone mineral density (BMD), commonly assessed by dual-energy X-ray absorptiometry (DXA). The Fracture Risk Assessment Tool (FRAX) estimates 10-year fracture risk. Saudi Arabia was recently included in FRAX, enabling population-specific risk estimation. Notably, FRAX can be applied with or without BMD, but limited Saudi data exist comparing both methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.